Patients with hypertrophic obstructive cardiomyopathy after alcohol septal ablation have favorable long-term outcome irrespective of their genetic background.
Cardiomyopathy
alcohol septal ablation (ASA)
genetics
hypertrophic cardiomyopathy (HCM)
hypertrophic obstructive cardiomyopathy
Journal
Cardiovascular diagnosis and therapy
ISSN: 2223-3652
Titre abrégé: Cardiovasc Diagn Ther
Pays: China
ID NLM: 101601613
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
entrez:
19
5
2020
pubmed:
19
5
2020
medline:
19
5
2020
Statut:
ppublish
Résumé
The genetic background of patients with hypertrophic cardiomyopathy (HCM) treated with alcohol septal ablation (ASA) and its relationship to the outcomes are not known. We aimed to investigate whether the outcome of genotype positive (G+) patients differs from genotype negative (G-) patients treated with ASA. We included 129 HCM patients (mean age 54±13 years) treated with ASA in a tertiary cardiovascular center and performed next generation sequencing (NGS) based genomic testing. All patients were followed-up three months after the procedure and yearly thereafter. A total of 30 (23%) HCM patients were G+ patients. At the 3-months follow-up, both groups of patients had similar left ventricular outflow tract PG (16.9±15.7 mmHg in G+ Despite more severe phenotype in G+ HCM patients, ASA is an equally effective treatment for LVOTO in G+ patients as it is for treating LVOTO in G- patients. The long-term outcome after ASA is similar in G+ and G- patients.
Sections du résumé
BACKGROUND
BACKGROUND
The genetic background of patients with hypertrophic cardiomyopathy (HCM) treated with alcohol septal ablation (ASA) and its relationship to the outcomes are not known. We aimed to investigate whether the outcome of genotype positive (G+) patients differs from genotype negative (G-) patients treated with ASA.
METHODS
METHODS
We included 129 HCM patients (mean age 54±13 years) treated with ASA in a tertiary cardiovascular center and performed next generation sequencing (NGS) based genomic testing. All patients were followed-up three months after the procedure and yearly thereafter.
RESULTS
RESULTS
A total of 30 (23%) HCM patients were G+ patients. At the 3-months follow-up, both groups of patients had similar left ventricular outflow tract PG (16.9±15.7 mmHg in G+
CONCLUSIONS
CONCLUSIONS
Despite more severe phenotype in G+ HCM patients, ASA is an equally effective treatment for LVOTO in G+ patients as it is for treating LVOTO in G- patients. The long-term outcome after ASA is similar in G+ and G- patients.
Identifiants
pubmed: 32420099
doi: 10.21037/cdt.2020.01.12
pii: cdt-10-02-193
pmc: PMC7225433
doi:
Types de publication
Journal Article
Langues
eng
Pagination
193-200Informations de copyright
2020 Cardiovascular Diagnosis and Therapy. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/cdt.2020.01.12). The authors have no conflicts of interest to declare.
Références
Heart. 2016 Nov 15;102(22):1793-1796
pubmed: 27587438
Mayo Clin Proc. 2008 Jun;83(6):630-8
pubmed: 18533079
J Am Coll Cardiol. 2012 Aug 21;60(8):705-15
pubmed: 22796258
Genet Med. 2017 Feb;19(2):192-203
pubmed: 27532257
Mayo Clin Proc. 2006 Apr;81(4):459-67
pubmed: 16610565
J Cardiovasc Transl Res. 2016 Apr;9(2):153-61
pubmed: 26914223
Heart. 2015 Feb;101(4):294-301
pubmed: 25351510
Circ Genom Precis Med. 2019 Feb;12(2):e002460
pubmed: 30681346
Circulation. 2011 Dec 13;124(24):e783-831
pubmed: 22068434
Eur Heart J. 2014 Oct 14;35(39):2733-79
pubmed: 25173338
Int J Cardiol. 2019 Mar 1;278:173-179
pubmed: 30554928
Genet Med. 2015 Nov;17(11):880-8
pubmed: 25611685
J Med Genet. 2011 Aug;48(8):572-6
pubmed: 21239446
Genet Med. 2018 Jan;20(1):69-75
pubmed: 28640247
Kardiol Pol. 2019;77(2):160-161
pubmed: 30816984
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Eur Heart J. 2016 May 14;37(19):1517-23
pubmed: 26746632
Arch Med Sci. 2019 May;15(3):641-649
pubmed: 31110529
Circulation. 2018 Oct 2;138(14):1387-1398
pubmed: 30297972
Mayo Clin Proc. 2014 Jun;89(6):727-37
pubmed: 24793961
Circ Cardiovasc Genet. 2011 Apr;4(2):110-22
pubmed: 21252143
Can J Cardiol. 2018 Jan;34(1):16-22
pubmed: 29275877
Med Sci Monit. 2007 Apr;13(4):RA62-8
pubmed: 17392660
Catheter Cardiovasc Interv. 2014 Jul 1;84(1):101-7
pubmed: 24285605